<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 7:     Effect of Voriconazole on Pharmacokinetics of Other Drugs [see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)] 
			</caption>
<tfoot>
<tr>
<td align="justify" colspan="78">
<sup>*</sup>  Results based on <content stylecode="italics">in vivo</content> clinical studies generally following repeat oral dosing with 200 mg BID voriconazole to healthy subjects<br/>
<sup>**</sup> Results based on <content stylecode="italics">in vivo</content> clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects <br/>
<sup>***</sup> Results based on <content stylecode="italics">in vivo</content> clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for 4 days voriconazole to subjects receiving a methadone maintenance dose (30-100 mg q24h)<br/>
<sup>****</sup>  Non-Steroidal Anti-Inflammatory Drug <br/>
<sup>*****</sup> Non-Nucleoside Reverse Transcriptase Inhibitors<br/>
</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Drug/Drug Class <br/>            (Mechanism of Interaction by Voriconazole)</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Drug Plasma Exposure </content>
<br/>
<content stylecode="bold">(C<sub>max</sub> and AUC<sub>τ</sub>)</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Recommendations for Drug Dosage Adjustment/Comments</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Sirolimus* <br/>(CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Rifabutin* <br/>(CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Efavirenz (400 mg q24h)** (CYP3A4 Inhibition) <br/> <br/>Efavirenz (300 mg q24h)** (CYP3A4 Inhibition) <br/> <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly  Increased<br/> <br/> <br/>Slight Increase in<content stylecode="bold"></content>AUC<sub>τ</sub>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/> <br/> <br/>When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">High-dose Ritonavir (400 mg q12h)** (CYP3A4 Inhibition) <br/>
<br/>            Low-dose Ritonavir (100 mg q12h)** <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">No Significant Effect of Voriconazole on Ritonavir C<sub>max</sub> or AUC<sub>τ</sub>
<br/>
<br/>            Slight Decrease in Ritonavir C<sub>max</sub> and AUC<sub>τ</sub>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>because of significant reduction of voriconazole C<sub>max</sub> and AUC<sub>τ</sub>
<br/>
<br/>
<br/>            Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided (due to the reduction in voriconazole C<sub>max</sub> and AUC<sub>τ</sub>) unless an assessment of the benefit/risk to the patient justifies the use of voriconazole<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Terfenadine, Astemizole, Cisapride, Pimozide, Quinidine (CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated </content>because of potential for QT prolongation and rare occurrence of <content stylecode="italics">torsade de pointes</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Ergot Alkaloids <br/>(CYP450 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Contraindicated</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Cyclosporine* <br/>(CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">AUC<sub>τ</sub> Significantly Increased; No Significant Effect on C<sub>max</sub>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">When initiating therapy with voriconazole tablets in patients already receiving cyclosporine, reduce the cyclosporine dose to one-half of the starting dose and follow with frequent monitoring of cyclosporine blood levels. Increased cyclosporine levels have been associated with nephrotoxicity. When voriconazole tablets are discontinued, cyclosporine concentrations must be frequently monitored and the dose increased as necessary.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Methadone*** (CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Fentanyl<br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Reduction in the dose of fentanyl and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole<content stylecode="bold"></content>tablets. Extended and frequent monitoring for opiate-associated adverse events may be necessary [<content stylecode="italics">see Drug Interactions (<linkhtml href="#Section_7">7</linkhtml>)</content>]<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Alfentanil<br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Reduction in the dose of alfentanil and other opiates metabolized by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole tablet. A longer period for monitoring respiratory and other opiate-associated adverse events may be necessary [<content stylecode="italics">see Drug Interactions (<linkhtml href="#Section_7">7</linkhtml>)</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Oxycodone<br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Reduction in the dose of oxycodone and other long-acting opiates metabolized by CYP3A4 should be considered when coadministered with voriconazole<content stylecode="bold"></content>tablets. Extended and frequent monitoring for opiate-associated adverse events may be necessary [<content stylecode="italics">see Drug Interactions (<linkhtml href="#Section_7">7</linkhtml>)</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">NSAIDs**** including ibuprofen and diclofenac<br/>(CYP2C9 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity related to NSAIDs. Dose reduction of NSAIDs may be needed [<content stylecode="italics">see Drug Interactions (<linkhtml href="#Section_7">7</linkhtml>)</content>].<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Tacrolimus*<br/>(CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<content stylecode="bold"> </content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">When initiating therapy with voriconazole tablets in patients already receiving tacrolimus, reduce the tacrolimus dose to one-third of the starting dose and follow with frequent monitoring of tacrolimus blood levels. Increased tacrolimus levels have been associated with nephrotoxicity. When voriconazole<content stylecode="bold"></content>tablets are discontinued, tacrolimus concentrations must be frequently monitored and the dose increased as necessary.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Phenytoin*<br/>(CYP2C9 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring of phenytoin plasma concentrations and frequent monitoring of adverse effects related to phenytoin.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Oral Contraceptives containing ethinyl estradiol and norethindrone<br/>(CYP3A4 Inhibition)**<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Monitoring for adverse events related to oral contraceptives is recommended during coadministration.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Warfarin*<br/>(CYP2C9 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Prothrombin Time Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Monitor PT or other suitable anti-coagulation tests. Adjustment of warfarin dosage may be needed.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Omeprazole* <br/>(CYP2C19/3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Significantly Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">When initiating therapy with voriconazole<content stylecode="bold"></content>tablets in patients already receiving omeprazole doses of 40 mg or greater, reduce the omeprazole dose by one-half. The metabolism of other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of other proton pump inhibitors.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Other HIV Protease Inhibitors <br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="italics">In Vivo </content>Studies Showed No Significant Effects on Indinavir Exposure <br/>
<content stylecode="italics"> </content>
<br/>
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">No dosage adjustment for indinavir when coadministered with voriconazole tablets<br/> <br/> <br/>Frequent monitoring for adverse events and toxicity related to other HIV protease inhibitors<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Other NNRTIs***** (CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for Voriconazole to Inhibit Metabolism of Other NNRTIs (Increased Plasma Exposure)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity related to NNRTI<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Benzodiazepines <br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity (i.e., prolonged sedation) related to benzodiazepines metabolized by CYP3A4 (e.g., midazolam, triazolam, alprazolam). Adjustment of benzodiazepine dosage may be needed.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">HMG-CoA Reductase Inhibitors (Statins) <br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure)<content stylecode="bold"></content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity related to statins. Increased statin concentrations in plasma have been associated with rhabdomyolysis. Adjustment of the statin dosage may be needed.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Dihydropyridine Calcium Channel Blockers <br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="italics">In Vitro </content>Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity related to calcium channel blockers. Adjustment of calcium channel blocker dosage may be needed.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Sulfonylurea Oral Hypoglycemics <br/>(CYP2C9 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. Adjustment of oral hypoglycemic drug dosage may be needed.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">Vinca Alkaloids (CYP3A4 Inhibition) <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo </content>or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Frequent monitoring for adverse events and toxicity (i.e., neurotoxicity) related to vinca alkaloids. Adjustment of vinca alkaloid dosage may be needed.<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">Everolimus <br/>(CYP3A4 Inhibition)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Drug Plasma Exposure Likely to be Increased <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Concomitant administration of <br/>voriconazole and everolimus is not recommended. <br/>
</td>
</tr>
</tbody>
</table>